Analysts: Disney Reaction Is Overdone and 3 More Research Notes to Catch Up On
Disney (NYSE:DIS): UBS says that the reaction to Disney’s slight lowering of Q3 guidance is way overdone, and that the core thesis remains intact. The firm keeps a Buy rating on the shares.
Scotts Miracle-Gro (NYSE:SMG): BMO Capital has downgraded the company based on valuation concerns coupled with high Street estimates. It now rates the shares at Underperform, from Market Perform, with a price target of $43.
Splunk Inc. (NASDAQ:SPLK): After better than expected Q4 results, Susquehanna has raised its price target on Splunk from $45 to $52, based on increased guidance, new business momentum, and growing awareness as evidenced by new customers making larger up-front purchases. It rates the shares at Positive.
BioMarin Pharmaceuticals (NASDAQ:BMRN): RW Baird believes BioMarin could be under pressure today following its announcement of a three month PDUFA extension into 2014 of its Vimizim drug, and assumed a late 2013 approval although changes to estimates wouldn’t change the price target. It recommends buying shares on weakness, and keeps an Outperform rating with a $69 price target.
Don’t Miss: Is Wal-Mart Finally Dealing With Factory Safety?